Founded in 2021, GAIRI is a collaborative R&D platform tackling the biggest challenges in medicine. Our select membership of leading global life sciences, technology, healthcare and academic organizations are together developing novel causal artificial intelligence and machine learning (AI/ML) and unconventional computing strategies for understanding human biology – and then applying these to deliver better medicine and improve health for people around the world.

Breaking down barriers to solve big problems

GAIRI is following the example of the collaborative R&D engines that revolutionized telecommunications, electronics and theoretical physics to accelerate the development and application of AI/ML solutions to medicine and healthcare. By convening leaders from across industry and academia, we aim to eliminate the bottlenecks of traditional scientific and applied research; de-risk the development of new tools, approaches and products; and provide a direct link between innovation and medical impact. 


The leading AI/ML toolbox in human biology

Genuity's AI team has a long track record of landmark advances in the application of machine learning and unconventional computing to human biology. Peer-reviewed and published, these innovations span a broad range of capabilities and diseases, with applications from drug discovery and development to digital medicine, including:

  • Novel, in vivo-validated causal dependency models of the drivers of disease initiation and progression
  • Focused single-cell experimentation and generative AI/ML to identify aberrant cell populations driving disease
  • Automated disease classification for diagnostics, clinical trials and precision medicine
  • Novel natural language processing (NLP) and digital imaging know-how for phenomapping in clinical care
  • Pioneering applications of quantum approaches to human multiomics data, uncovering robust and replicable signals and drug targets in small patient cohorts

Uniquely advancing new methods AND pathbreaking products

GAIRI is bringing together industry and academic leaders not only to push the leading-edge of AI/ML strategies and tools, but to speed their use in bringing to market products to benefit patients.

Members have a seat at the table to help to choose the next big challenges to solve in AI/ML, probabilistic programming and unconventional computing, as well as real-time access to novel tools and algorithms as they are developed for use by their own teams. 

To speed the application of these methodological advances, members have privileged access to the Genuity AI team to work on their in-house programs, as well as the an insider view of and ability to help to direct and partner on Genuity's target discovery and development programs in cardiovascular disease, cancer, NASH and Alzheimer's, among others.

Genuity's AI/ML team publishes its discoveries and novel methods in leading peer-reviewed journals. Below are a selection of recently published breakthrough contributions, from the first successful application of quantum approaches to human multiomics data to in vivo-validated causal biology in cardiovascular disease. 

Nature metabolism (1)

Quantum processor-inspired machine learning in the biomedical sciences

Read more.

Smooth Muscle Cell Reprogramming in Aortic Aneurysms

Read more.

Chronic mTOR activation induces a degradative smooth muscle cell phenotype

Read more.

Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis

Read more.


Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium. Read more.


Enhancing retrosynthetic reaction prediction with Deep Learning using multiscale reaction classification. Read more.

journal proteome

Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2. Read more.


Somatic mutation in single human neurons tracks developmental and transcriptional history .Read more.


FGF-dependent metabolic control of vascular development Read more.


Aging & neurodegeneration are associated with increased mutations in single human neurons Read more.


Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification Read more.


Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment Read more.


Tom circle
jose circle-1
allison circle

Tom Chittenden, PhD, DPhil, PStat

Chief Technology Officer
President and Founding Director, Genuity AI Research Institute

Tiago Magalhaes, PhD

Director of Computational Biology

Jose Malagon Lopez, PhD

Director of Computational Statistics

Allison McLean

AI Lab Manager

See all openings

Are you interested in learning more about GAIRI membership?